Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136513 · ClinicalTrials.gov registry record · Phase 1
SB-743921 In Patients With Solid Tumors
A Phase 1 study of Solid Tumor Cancer, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT00136513: Completed Phase 1 study of Solid Tumor Cancer, sponsored by GlaxoSmithKline.
NCT00136513 is a Phase 1 study of Solid Tumor Cancer that has completed, run by GlaxoSmithKline. The registered enrollment target is 30 participants, below the 853-participant average among 10 other Solid Tumor Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00136513, a Phase 1 study of Solid Tumor Cancer, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to find a dose of SB-743921 in adult patients with solid tumors or lymphoma who have progressed on standard therapy or who have relapsed. SB-743921 is dosed by 1-hour intravenous infusion every 3 weeks. A patient may continue to receive treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of the drug in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment with SB-743921. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.
Conditions Studied
Interventions
- DRUG SB-743921
Study Locations (2)
Pennsylvania
- GSK Investigational Site - Pittsburgh
Wisconsin
- GSK Investigational Site - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-04 |
| Phase | Phase 1 |
What the finished NCT00136513 record still lists
NCT00136513 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 853-participant average among 10 other Solid Tumor Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Solid Tumor Cancer appearing as the primary indexed condition, and to 1 intervention - of which SB-743921 is the first listed.
NCT00136513 reports a single indexed study location in Pennsylvania, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00136513 about?
NCT00136513 is a clinical study titled "SB-743921 In Patients With Solid Tumors". The purpose of this study is to find a dose of SB-743921 in adult patients with solid tumors or lymphoma who have progressed on standard therapy or who have relapsed. SB-743921 is dosed by 1-hour intravenous infusion every 3 weeks. A patient may continue to receive treatment as long as they are bene...
What is the current status of trial NCT00136513?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2004-04.
What conditions does trial NCT00136513 study?
This clinical trial studies the following conditions: Solid Tumor Cancer.
What interventions are being tested in trial NCT00136513?
The interventions under investigation include: SB-743921 (DRUG).
Who is sponsoring clinical trial NCT00136513?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00136513 being conducted?
This trial has 2 study locations across Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00136513's enrollment target sits among peer trials
30 10th of 10 higher than 1 of 10 other Solid Tumor Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
RECRUITING · Phase 1
-
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
RECRUITING · Phase 1
-
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
RECRUITING · Phase 1
-
Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors
COMPLETED · Phase 1
-
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia